

In-Depth Analysis Of The Minimal Residual Disease Market: Key Drivers, Trends, Growth Opportunities And Forecast 2034

The Business Research Company's Minimal Residual Disease Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, March 26, 2025
/EINPresswire.com/ -- Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.



With the number of cancer patients rapidly escalating and healthcare becoming more accessible worldwide, the <u>minimal residual disease market</u> size has expanded rapidly. In light of the rising prevalence of blood cancer and substantial investment in research and development, the market size has grown from \$1.78 billion in 2024 to an estimated \$2.01 billion in 2025, exhibiting a compound annual growth rate CAGR of 12.9%.

What are The Market Projections for The Minimal Residual Disease Sector? The minimal residual disease market is set to experience soaring growth over the coming years. With a predicted CAGR of 12.5%, the market is expected to grow to \$3.22 billion in 2029. This surge is largely due to an increase in patients with cancer, bolstered government awareness programs, enhanced healthcare affordability, and augmented disposable income in emerging economies. Furthermore, various government initiatives to spread awareness about cancer are also contributing to this impressive market growth.

Get Your Free Sample Market Report:

https://www.thebusinessresearchcompany.com/sample_request?id=21224&type=smp

What Are the Key Market Drivers?

One of the leading drivers behind the boom in the minimal residual disease market is the escalating prevalence of cancer. Cancer, a group of diseases characterized by the uncontrolled growth and the propagation of abnormal cells in the body, is spreading largely due to factors like an aging population, increased exposure to environmental carcinogens, unhealthy lifestyles, and

genetic predispositions. To combat this rising menace, there is an increasing demand for precise MRD testing to detect residual cancer cells, leading to early intervention and personalized treatment. This technique significantly enhances patient outcomes by improving relapse prediction.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/minimal-residual-disease-global-market-report

Who Are the Key Industry Players?

The minimal residual disease market boasts a multitude of major companies, including Thermo Fisher Scientific Inc., Amgen Inc., Laboratory Corporation of America Holdings LabCorp, Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Kite Pharma Inc., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Grail LLC, Tempus Al Inc., Veracyte Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., and ArcherDx Inc.

What are the Emerging Trends?

Significant advancements are being made in the minimal residual disease market, with players focusing on developing innovative in vitro diagnostic IVD test services to provide personalized therapy options for better patient outcomes. For instance, in December 2022, Adaptive Biotechnologies Corporation launched the clonoSEQ Assay to detect minimal residual disease MRD in patients with diffuse large B-cell lymphoma DLBCL. This revolutionary test analyzes circulating tumor DNA ctDNA in blood samples to monitor cancer progression and detect early signs of relapse in a non-invasive manner, fundamentally altering the approach to cancer treatment.

How is the Minimal Residual Disease Market Segmented?

This report explores various market segments within this sector:

- 1 By Detection Target: Lymphoma, Leukemia, Solid Tumors, Other Detection Targets.
- 2 By Test Technique: Flow Cytometry, Polymerase Chain Reaction PCR, Next Generation Sequencing NGS, Other Test Techniques.
- 3 By End-User: Banking, Financial Services, And Insurance BFSI, Retail And E-Commerce, Hospitals, Diagnostic Laboratories, Research Institutions.

Under the umbrella of these segments, there are several subsegments, including:

- 1 By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma.
- 2 By Leukemia: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia.
- 3 By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer.
- 4 By Other Detection Targets: Multiple Myeloma, Neuroblastoma, Sarcomas.

What are the Regional Insights?

While North America was the largest region in the minimal residual disease market in 2024, Asia-Pacific is expected to be the fastest-growing region in the upcoming forecast period.

Browse Through More Similar Reports By The Business Research Company:

Inflammatory Bowel Disease Treatment Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Chronic Disease Management Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

Liver Diseases Therapeutics Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

About The Business Research Company

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Equipped with 1,500,000 datasets, indepth secondary research, and unique insights from industry leaders, we provide the information you need to stay ahead of the competition.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/ Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708 Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company/ YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/797262941

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.